Fig. 2.

Putting the risks of osteoporotic fracture vs. rare adverse events into perspective. Adapted from Brown et al. [48]. DMAb-AFF, denosumab-associated atypical subtrochanteric and diaphyseal femur fracture; Bis-AFF, bisphosphonate-associated atypical subtrochanteric and diaphyseal femur fracture; DMAb-ONJ, denosumab-associated osteonecrosis of the jaw; Bis-ONJ, bisphosphonate-associated osteonecrosis of the jaw; MVA, motor vehicle accident; MOF, major osteoporotic fracture. ^a10-Year risk of major osteoporotic fracture by Canadian Fracture Risk Assessment Tool.